Anavex life sciences reports new publication in medical journal highlighting the relevance of sigmar1 activation to compensate for early alzheimer's disease

Mechanism of action of anavex®2-73 (blarcamesine) and anavex®3-71 (af710b) is the activation of sigmar1

AVXL Ratings Summary

AVXL Quant Ranking